--- a
+++ b/clusters/9knumclustersv2/clust_1327.txt
@@ -0,0 +1,184 @@
+Life expectancy of at least  months from most recent chemotherapy or immunotherapy treatment
+No comorbid conditions that would cause life expectancy of less than  years
+Patients must have a life expectancy of >=  weeks as determined clinically by the treating physician
+Life expectancy of at least  weeks based on investigator estimate
+Have ECOG PS of  or  with an anticipated life expectancy of >  months.
+Life expectancy < years
+Life expectancy of >  months as defined by agreement of both the Chow et al. and TEACHH models
+SAFETY RUN-IN: Life expectancy of less than  months
+Subject must have a life expectancy >=  years
+PIKCA WILD TYPE COHORT (closed //): Life expectancy >  months
+Patients with life expectancy >=  weeks from time of CTL infusion
+Life expectancy of at least  months in the judgment of the physician
+No prior primary or metastatic brain or meningeal tumors unless clinically and radiographically stable as well as off steroid therapy for at least  months; a. Life expectancy ? weeks all (US); b. Life expectancy ? weeks; ?  weeks superficial tumors (Canada);
+Patients with short life expectancy (less than  months) due to comorbidity other than MDS or CMML
+Life expectancy ? mos
+Life expectancy ? years, as judged by the site investigator
+Life expectancy of less than  months in the judgment of the study physician.
+Patients with a life expectancy <  months from co-existing disease other than the leukemia or RAEB
+Life expectancy >=  days
+Must have a life expectancy of at least  years based on age and comorbidities but excluding diagnosis of breast cancer.
+Patients with a life expectancy of less than  years
+No active or co-existing malignancy with life expectancy less than  months
+No active or co-existing malignancy with life expectancy less than  months
+Life expectancy >=  weeks as judged by the treating physician.
+Life expectancy >=  days
+Co-existing medical conditions with life expectancy <  years
+Patients with a life expectancy of <  months of enrollment from coexisting disease other than leukemia
+Life expectancy less than  years;
+Patients must have life-expectancies >  months to be included in the trial
+Life expectancy of at least  years
+Life expectancy >=  months at the time of study drug administration
+Minimum life expectancy of at least  weeks. Expanded Safety Phase:
+Patients with any severe concomitant disease that may limit their life expectancy to less than  years
+Life expectancy of ?  months from the first OBP- treatment.
+Life expectancy <  months (as estimated per diagnosis-specific graded prognostic assessment [ds-GPA])
+Life expectancy of over  months as determined by treating physician
+Life expectancy less than  years
+Patients with short life expectancy (less than  months) due to comorbidity other than MDS
+Life expectancy of >=  weeks based on investigator estimate
+ECOG Grade  - , with minimum life expectancy of at least  months;
+Patients with life expectancy of =<  months for reasons other than their underlying hematologic/oncologic disorder
+Presence of other comorbid illnesses with an estimated median life expectancy <  years
+Subject has an ECOG Performance Status - and anticipated life expectancy > months prior to apheresis and > months prior to lymphodepletion.
+Life expectancy of greater than  months (does not apply to pancreatic cancer population)
+Have at least  month life expectancy
+Subjects must have a reasonable life expectancy of at least  months
+Life expectancy =<  months in the judgment of the treating clinician
+Life expectancy > weeks as judged by investigators
+Life expectancy of >=  weeks (per treating investigators discretion)
+Life expectancy >=  years (as determined by the treating physician)
+CAPMATINIB INCLUSION CRITERIA: Life expectancy >=  weeks
+CERITINIB INCLUSION CRITERIA: Life expectancy >=  weeks
+Patients with life expectancy of =<  months for reasons other than their underlying hematologic/oncologic disorder
+No active or co-existing malignancy with life expectancy less than  months
+Life expectancy >=  weeks excluding their diagnosis of breast cancer
+Life expectancy with treatment should be >=  months in the estimation of the treating physicians
+A life expectancy of at least  weeks, even if requiring artificial ventilation.
+Life expectancy of at least  years
+Life expectancy of >=  years (yrs)
+Other serious medical conditions that may be expected to limit life expectancy to less than  years (e.g., liver cirrhosis).
+At least  month life expectancy
+Life expectancy >  years
+Must have a life expectancy of at least  years based on age and co-morbidities.
+Patients with life expectancy of =<  months for reasons other than their underlying hematologic/oncologic disorder
+Life expectancy of greater than  months to allow completion of study treatment and assessment of dose-limiting toxicity
+Patients with life expectancy of =<  months for reasons other than their underlying hematologic/oncologic disorder
+A life expectancy of at least  months with a Karnofsky performance status of at least 
+Patients with life expectancy of =<  months for reasons other than their underlying hematologic/oncologic disorder
+Minimum life expectancy of six weeks as determined by consenting professional
+No life expectancy restrictions will apply
+Life expectancy of >=  years as determined by treating physician
+Patients with co-existing medical conditions with life expectancy <  years
+Life expectancy reasonably adequate for evaluating the treatment effect
+A serious underlying medical condition other than NSCLC such that life expectancy is less than  years.
+INCLUSION CRITERIA FOR CCT: minimum life expectancy of eight weeks
+life expectancy of less than  months; Related to anticoagulant treatment:
+Life expectancy of at least  days
+Stable clinical conditions and life expectancy >  months
+Other life-threatening illness that is expected to impact life expectancy within  years
+The patient has a prior or concurrent malignancy that in the opinion of the investigator, presents a greater risk to the patients health and survival, than of the MCL with a life expectancy <  years.
+Life expectancy of >=  months in the attending physicians estimation
+Life expectancy estimate >  months
+Life expectancy of >  years per the clinical impression of the treating physician(s)
+Life expectancy >  months as assessed by study physician
+TUMOR BIOPSY SEQUENCING: Life expectancy >  months
+Life expectancy of >=  years
+Minimum expected life expectancy >  months
+<  years life expectancy
+Life expectancy <  years
+Life expectancy of at least  months based on Investigators judgment.
+Life expectancy ?  years
+Life expectancy of at least  years, disregarding the diagnosis of cancer;
+ECOG Performance Status - and anticipated life expectancy >  months.
+Patients with other active malignancies (no evidence of other cancer or life expectancy greater than  years) are ineligible for this study
+Life expectancy ?  years.
+Life expectancy >=  months at the time of study drug administration
+Diagnosis of a coexisting medical condition which limits life expectancy to <  years
+Life expectancy of at least  years
+Life expectancy <  days.
+Have ECOG PS of  or  with an anticipated life expectancy of >  months.
+Patients must have an anticipated life expectancy >  months.
+Patients must have a life expectancy of >=  days
+Life expectancy <  months as assessed by the treating physician
+Patient ?  years of age. Patient life expectancy >  months. Eastern cooperative group (ECOG) of  or 
+Life expectancy >  years
+Life expectancy of at least  years from the time of diagnosis, not considering the melanoma in question, as determined by the PI.
+Life expectancy of < months and/or has rapidly progressing disease
+Subject must be ?  years of age. Life expectancy >  weeks.
+Patients must have a life expectancy >=  days
+Life expectancy >=  months as determined by the treating physician
+Life expectancy >  month
+Life expectancy <  years
+Patients with life expectancy of =<  months for reasons other than their underlying hematologic/oncologic disorder
+At least -month life expectancy.
+Life expectancy >  years based on clinicians judgment
+Life expectancy less than  month
+Patients with a life expectancy <  months from co-existing disease other than the leukemia or RAEB
+Patients may have received therapy for other malignancies, as long as they have completed therapy at least  months prior to study entry and be deemed to have a life expectancy of at least  years with regard to that malignancy
+Life expectancy >=  mos
+Other serious medical conditions that may be expected to limit life expectancy to less than  years (e.g., liver cirrhosis).
+Life-expectancy based on comorbid conditions >  years
+Patients must have a life expectancy of >=  months and a Karnofsky performance status >= 
+Life expectancy from a co-morbid illness >  years
+Known history of or concomitant malignancy likely to affect life expectancy in the judgment of the investigator
+Life expectancy of at least  years
+Any available standard line of therapy known to be life-prolonging or life-saving
+Life expectancy of at least  weeks ( months) as determined by the treating physician.
+Patients with life expectancy of =<  months for reasons other than their underlying hematologic/oncologic disorder or complications there from
+Anticipated life expectancy > months at the time of screening
+Anticipated life expectancy > months at the time of screening
+Life-expectancy of at least  days
+Life expectancy of at least  months in the judgment of the physician
+are eligible for any standard therapy known to be life prolonging or life saving
+History of second malignancies with life expectancy of <  years or requirement of therapy that would confound study results. This does not include the following:
+Life expectancy >mo.
+Any co-morbid condition that poses a greater threat to the patients life expectancy than the recurrent myeloma
+No concurrent malignancy with a life expectancy of less than two years, or one that requires ongoing chemotherapeutic intervention at screening
+Subject has concurrent severe or uncontrolled medical disease or organ system dysfunction which, in the opinion of the Investigators, would limit life expectancy to <  months.
+Anticipated life expectancy >  months at the time of screening
+Not eligible for or declined transplantation or any standard therapy known to be life prolonging or life saving
+Patients life expectancy is >=  years
+Patients with other active malignancies (no evidence of other cancer or life expectancy greater than  years) are ineligible for this study
+Life expectancy of at least  month
+Life expectancy of at least  months in the judgment of the physician
+No co-existing medical conditions with life expectancy <  years
+PATIENT EXCLUSION: Life expectancy of <  month
+Patients must have a life expectancy of  days
+Must have a life expectancy >  days
+There are no restrictions related to performance status or life expectancy
+Patients with a life expectancy of =<  months, as determined by their oncology providers, will be excluded
+Patients are eligible regardless of life expectancy
+PATIENTS ONLY: Physician-rated life expectancy of less than  months
+Attending physician assessment of prognosis with expected life expectancy of >  months
+Severe co-existing morbidities having a life expectancy of less than  days
+No life expectancy restriction
+There are no restrictions related to performance status or life expectancy
+Has a life expectancy of  months or longer; all cancer types are included
+There are no restrictions related to performance status and life expectancy
+Life expectancy >=  days
+Have a life expectancy > months from the anticipated time of initiation of treatment
+Participants must have a life expectancy of  years or more
+>=  months life expectancy (physician estimate)
+No restrictions will be made based on life expectancy
+Life expectancy less than  years
+EXCLUSION CRITERIA FOR ENROLLMENT (PRE-TRANSPLANT): Non-hematologic malignancy with a life expectancy of <  years
+Suffering from a terminal illness with less than  month life expectancy
+Terminal illness with less than  month life expectancy
+Subjects with a life expectancy less than study duration;
+Life expectancy < months or Lansky score <%
+Life expectancy of >=  years
+Life expectancy less than five years.
+Patients with anticipated life expectancy <  months will be excluded
+Life expectancy <  months (mo)
+Patients being considered for RALP and pelvic lymphadenectomy with life expectancy greater than  years as determined by treating physician
+Life expectancy >=  years
+There are no life expectancy restrictions
+Subject must have a life expectancy that exceeds the duration of the clinical trial
+Individuals with a short life expectancy (<  years)
+There are no restrictions on life expectancy
+Life expectancy is not a consideration for protocol entry
+Life expectancy of >=  months (as determined by treating physician)
+A referring physicians estimate of patient life expectancy must be between - months
+Patients with life expectancy of at least  months and who are expected to be able to complete the full follow-up assessment in the protocol.
+Patients with distant metastatic disease (cM) or a life expectancy of less than  years